Kristian Reich Sells 43,700 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) insider Kristian Reich sold 43,700 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $20.09, for a total transaction of $877,933.00. Following the completion of the sale, the insider owned 2,764,746 shares of the company’s stock, valued at $55,543,747.14. This trade represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kristian Reich also recently made the following trade(s):

• On Monday, July 27th, Kristian Reich sold 1,100 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $20.00, for a total value of $22,000.00.
• On Tuesday, July 21st, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $20.02, for a total value of $1,001,000.00.
• On Wednesday, June 17th, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $19.43, for a total value of $971,500.00.
• On Monday, June 15th, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $18.89, for a total value of $944,500.00.

MoonLake Immunotherapeutics Trading Down 1.8%

NASDAQ MLTX opened at $18.38 on Thursday. The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The firm has a market capitalization of $1.35 billion, a PE ratio of -4.75 and a beta of 1.04. The stock’s 50 day moving average is $19.11 and its 200 day moving average is $17.84.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.07). Research analysts forecast that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Large investors have recently modified their holdings of the stock. Weiss Asset Management LP grew its position in MoonLake Immunotherapeutics by 413.1% during the 1st quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company’s stock valued at $31,843,000 after purchasing an additional 1,375,367 shares during the last quarter. Candriam S.C.A. raised its holdings in MoonLake Immunotherapeutics by 509.0% in the first quarter. Candriam S.C.A. now owns 818,126 shares of the company’s stock worth $15,250,000 after buying an additional 683,797 shares during the last quarter. UBS Group AG raised its holdings in MoonLake Immunotherapeutics by 183.4% in the fourth quarter. UBS Group AG now owns 239,020 shares of the company’s stock worth $3,150,000 after buying an additional 154,673 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of MoonLake Immunotherapeutics in the fourth quarter worth approximately $1,176,000. Finally, Fox Run Management L.L.C. lifted its stake in shares of MoonLake Immunotherapeutics by 531.2% in the fourth quarter. Fox Run Management L.L.C. now owns 71,962 shares of the company’s stock worth $948,000 after buying an additional 60,562 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Analyst Upgrades and Downgrades

MLTX has been the topic of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Leerink Partners boosted their price objective on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Needham & Company LLC upped their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, July 20th. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and an average target price of $24.21.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.